[go: up one dir, main page]

ATE552344T1 - Viren mit erhöhter lytischer kraft - Google Patents

Viren mit erhöhter lytischer kraft

Info

Publication number
ATE552344T1
ATE552344T1 AT03729255T AT03729255T ATE552344T1 AT E552344 T1 ATE552344 T1 AT E552344T1 AT 03729255 T AT03729255 T AT 03729255T AT 03729255 T AT03729255 T AT 03729255T AT E552344 T1 ATE552344 T1 AT E552344T1
Authority
AT
Austria
Prior art keywords
viruses
target cells
increased lytic
functional
cells
Prior art date
Application number
AT03729255T
Other languages
English (en)
Inventor
Beusechem Victor Van
Willem-Ronald Gerritsen
Original Assignee
Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek En Patientenzorg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek En Patientenzorg filed Critical Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek En Patientenzorg
Application granted granted Critical
Publication of ATE552344T1 publication Critical patent/ATE552344T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03729255T 2002-01-14 2003-01-14 Viren mit erhöhter lytischer kraft ATE552344T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02075108A EP1327688A1 (de) 2002-01-14 2002-01-14 Adenoviren mit erhöhter Lysisfähigkeit
PCT/EP2003/000340 WO2003057892A2 (en) 2002-01-14 2003-01-14 Viruses with enhanced lytic potency

Publications (1)

Publication Number Publication Date
ATE552344T1 true ATE552344T1 (de) 2012-04-15

Family

ID=8185521

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03729255T ATE552344T1 (de) 2002-01-14 2003-01-14 Viren mit erhöhter lytischer kraft

Country Status (6)

Country Link
US (1) US8052965B2 (de)
EP (2) EP1327688A1 (de)
AT (1) ATE552344T1 (de)
AU (1) AU2003235764A1 (de)
ES (1) ES2385347T3 (de)
WO (1) WO2003057892A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2479763A1 (en) * 2002-03-27 2003-10-09 Baylor College Of Medicine Potent oncolytic herpes simplex virus for cancer therapy
US20110206639A1 (en) * 2004-04-15 2011-08-25 Christie Vermeulen Replication competent viruses capable of silencing virus inhibitory factor expression
EP1586654A1 (de) 2004-04-15 2005-10-19 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Replikationskompetente Viren für Genabschaltung von Virusinaktivierungsfaktor
CN105483093A (zh) 2005-06-23 2016-04-13 休斯顿大学 Ⅱ型单纯疱疹病毒突变体在治疗癌症中的用途
WO2007094653A1 (en) * 2006-02-13 2007-08-23 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Adenovirus particles having a chimeric adenovirus spike protein, use thereof and methods for producing such particles.
CN101432291B (zh) * 2006-02-28 2013-03-20 瓦克萨特公司 嵌合腺病毒载体
AU2007332980A1 (en) * 2006-07-26 2008-06-19 Intrexon Corporation Methods and compositions for treating disease
WO2011133040A2 (en) 2010-04-23 2011-10-27 Orca Therapeutics B.V. Replication-competent adenoviruses
WO2012047109A2 (en) 2010-10-08 2012-04-12 Orca Therapeutics B.V. Mirna and mirna inhibitors that modulate adenovirus replication and/or adenovirus induced cell death
WO2014153204A1 (en) 2013-03-14 2014-09-25 Salk Institute For Biological Studies Oncolytic adenovirus compositions
KR20210054067A (ko) 2013-06-14 2021-05-12 싸이오서스 테라퓨틱스 엘티디. 유형 b 아데노바이러스에 대한 투여 요법 및 제형
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
MX373835B (es) 2013-10-25 2020-07-08 Psioxus Therapeutics Ltd Adenovirus oncolíticos armados con genes heterólogos.
EP3198009B1 (de) 2014-09-24 2021-09-08 Salk Institute for Biological Studies Onkolytische tumorviren und verfahren zur verwendung
DK3288573T3 (da) 2015-04-30 2020-03-16 Psioxus Therapeutics Ltd Onkolytisk adenovirus, der koder for et b7-protein
BR112018012179A2 (pt) 2015-12-17 2018-12-04 Psioxus Therapeutics Ltd adenovírus de grupo b que codifica um anticorpo ou fragmento de complexo anti-tcr
CN105524161A (zh) * 2016-02-05 2016-04-27 南通大学 抗肿瘤小分子多肽piddδ及其载体和应用
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
CN108699566B (zh) 2016-02-23 2023-06-30 萨克生物研究学院 对病毒动力学影响最小的治疗性腺病毒中的外源基因表达
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
EP4273252A3 (de) 2016-08-29 2024-04-17 Akamis Bio Limited Adenovirus mit bispezifischem t-zell-engager (bite)
CA3045892A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
WO2019199859A1 (en) 2018-04-09 2019-10-17 Salk Institute For Biological Studies Oncolytic adenovirus compositions with enhanced replication properties
EP3844286A1 (de) 2018-08-31 2021-07-07 Orca Therapeutics B.V. Kompetente viren mit rekombinanter replikation mit einem codierenden bereich für glykogensynthase-kinase-3 (gsk3) und verfahren zum abtöten von anormalen zellen

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410010B1 (en) * 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
TW442569B (en) * 1993-10-25 2001-06-23 Canji Inc Recombinant adenoviral vector
US6638762B1 (en) * 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US6133243A (en) * 1996-02-22 2000-10-17 Onyx Pharmaceuticals, Inc. Liposomal-viral DNA complexes for treating disease
JP2000515504A (ja) * 1996-07-05 2000-11-21 フィリップ イー． ブラントン 細胞死を誘導するアデノウイルスｅ４蛋白質
US5981275A (en) * 1997-04-14 1999-11-09 Genzyme Corporation Transgene expression system for increased persistence
US6100086A (en) * 1997-04-14 2000-08-08 Genzyme Corporation Transgene expression systems
WO2000029573A2 (en) * 1998-11-18 2000-05-25 Canji, Inc. Adenoviral vectors
AU767904B2 (en) * 1999-05-12 2003-11-27 Uab Research Foundation, The Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
FR2794025A1 (fr) * 1999-05-25 2000-12-01 Transgene Sa Composition destinee a la mise en oeuvre d'un traitement antitumoral ou antiviral chez un mammifere
WO2001005437A2 (en) * 1999-07-15 2001-01-25 Introgen Therapeutics, Inc. Methods for treatment of hyperproliferative diseases using human mda-7
EP1238091A2 (de) * 1999-12-14 2002-09-11 Genovo, Incorporated Verfahren und zusammensetzungen zur herstellung von replicationsunfähigen adenovirus
WO2001074403A1 (en) * 2000-04-04 2001-10-11 Christopher Barry Wood Combination of p53 gene and e1b-deleted p53 gene
US20020187126A1 (en) * 2001-04-06 2002-12-12 Mount Sinai School Of Medicine Methods for viral oncoapoptosis in cancer therapy

Also Published As

Publication number Publication date
EP1466001B1 (de) 2012-04-04
WO2003057892A3 (en) 2004-02-26
AU2003235764A1 (en) 2003-07-24
WO2003057892B1 (en) 2004-05-13
EP1327688A1 (de) 2003-07-16
US20050220765A1 (en) 2005-10-06
WO2003057892A2 (en) 2003-07-17
EP1466001A2 (de) 2004-10-13
ES2385347T3 (es) 2012-07-23
US8052965B2 (en) 2011-11-08
AU2003235764A8 (en) 2003-07-24
EP1466001B8 (de) 2012-11-21

Similar Documents

Publication Publication Date Title
ATE552344T1 (de) Viren mit erhöhter lytischer kraft
ES2134346T3 (es) Virus citopatico para el tratamiento y la profilaxis de la neoplasia.
NO20024157L (no) Kasein-avledete peptider og anvendelser derav i terapi
DK1252323T3 (da) Virus-stammer til den onkolytiske behandling af cancer
BRPI0309631A8 (pt) vacina tetravalente da dengue contendo uma trivial deleção de 30 nucleotídeos na utr-31' dos tipos de dengue 1,2,3 e 4, ou de vírus antigênicos quiméricos da dengue 1,2,3 e 4
ATE277947T1 (de) Antitumorale zusammenstellung von immunogene polypetiden mit veränderter zellokalisierung
ATE157701T1 (de) Schnelle, vielseitige und einfache methode zur expression von genen in eukaryotischen zellen
BR0214650A (pt) Imunocitoquinas com seletividade modulada
FR2704234B1 (fr) Virus recombinants, preparation et utilisation en therapie genique.
DK0462187T3 (da) Farmaceutisk præparat, som kan anvendes til forebyggelse eller behandling af papillomvirusinducerede tumorer
WO2002086100A3 (en) Expression of core-glycosylated hcv envelope proteins in yeast
WO1998029555A3 (en) Cytopathic viruses for therapy and prophylaxis of neoplasia
AR054599A1 (es) Proteccion de la proteina krp mutante negativa dominante contra una inhibicion activa del complejo cdk -ciclina por la krp de tipo salvaje
UA85379C2 (ru) Рекомбинантный поксвирус, содержащий как минимум два ati промотора коровьей оспы
ATE346859T1 (de) Zusammensetzung zum zellspezifischen transfer von wirkstoffen
ATE226449T1 (de) Hilfsstoffe zur verwendung in adeno-assoziiertes virus enthaltenden pharmazeutischen zubereitungen und damit hergestellte pharmazeutische zubereitungen
ATE527356T1 (de) Replikationskompetente viren für genabschaltung von virusinaktivierung faktor
DK1404852T3 (da) Ekspression af gener i modificeret vacciniavirus Ankara ved anvendelse af kokoppe-ATI-promotoren
ES2044178T3 (es) Procedimiento de preparacion de 2-metil-5-terbutil-tiofenol.
WO2006038129A3 (en) Hepatitis c virus replication system
WO2004035616A3 (de) Adenovirus mit umgekehrter reihenfolge der expression von genen und verwendung davon
IL75553A (en) Dna sequence coding for a cholinesterase-like peptide, peptides produced by cells containing said dna and antibodies thereto
IL146191A0 (en) Viral expression vectors
ATE531730T1 (de) Immunogene hybridpolypeptide mit wirkung gegen obesitas und diese enthaltende impstoffzusammensetzung mit wirkung gegen obesitas
ES2169040T3 (es) Planta resistente a dos o mas virus y preparacion de la misma.